Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present HemaCare Corp. (OTC: HEMA).

Full DD Report for HEMA

You must become a subscriber to view this report.


Recent News from (OTC: HEMA)

HemaCare Reports Full Year 2017 Results
HemaCare Corporation (OTC Pink: HEMA), a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy, today announced operational highlights and financial results for the year ended December 31, 2017. 2017 Oper...
Source: Business Wire
Date: March, 08 2018 08:00
Notice of Annual Meeting of Shareholders Before Relocating to New Expansion Facility
HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, has announced that the Annual Meeting of Shareholders will be held at their corporate headquarters 15350 Sherman Way, Suite 423...
Source: Business Wire
Date: February, 20 2018 08:00
HemaCare and Charles River Laboratories Announce Strategic Partnership to Accelerate Drug Discovery and Development
PBMC humanization kits for NCG mouse models facilitate infectious disease and immuno-oncology research HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, and Charles R...
Source: Business Wire
Date: February, 06 2018 08:00
HemaCare Announces OneBlood Exercises Second Investment Tranche Option
HemaCare Corporation (OTCBB: HEMA), a leading provider of human-derived primary blood cells and tissues for biomedical research, has announced a second tranche investment, effective December 28, 2017, by a wholly-owned subsidiary of OneBlood, Inc., a not-for-profit blood center based in Flor...
Source: Business Wire
Date: January, 08 2018 06:00
HemaCare Plays Mission Critical Role in Global Cellular Therapy Development
For many years, HemaCare Corporation (OTCBB: HEMA) has been at the epicenter of cellular therapy, immunotherapy, and regenerative medicine research by providing researchers from biotech and pharma companies with mission critical human biological materials from reliable and recallable donor...
Source: Business Wire
Date: September, 12 2017 08:00
NetworkNewsBreaks - Top 10 Mid-day Percentage Gainers on August 23, 2017
Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: UCLE 19.59% – News: Posts Q2 2017 financial results BDIC 9.74% – News: Sales increase following billboard campaign MGTI 7.27% ...
Source: NetworkNewsWire
Date: August, 23 2017 13:00
HemaCare Will Attend Annual CAR-TCR Conference in Boston
HemaCare Corporation (OTCBB: HEMA), announced today that it will be attending the annual CAR-TCR conference September 5-8, 2017, in Boston, MA. The conference is focused on the development and commercialization of cell therapy that uses the immune system to fight cancer and other diseases....
Source: Business Wire
Date: August, 23 2017 08:00
HemaCare Reports Strong First Half 2017 Results
HemaCare Corporation (OTCBB:HEMA) today reported financial results for the six months ended June 30, 2017, showing continued robust gains in revenue, gross profit, and net income compared to the same period of 2016. Revenue from operations grew 50% to $8.7 million, while gross profit of $4...
Source: Business Wire
Date: August, 21 2017 08:00
HemaCare Signs Long Term Lease for Facility Relocation and Expansion
HemaCare Corporation (OTCBB: HEMA), a leading provider of human blood and immune cells for all stages of cell therapy development announced today that it has signed a long term lease to relocate its operations and corporate headquarters to a larger nearby site in the San Fernando Valley (C...
Source: Business Wire
Date: July, 24 2017 06:00
HemaCare Announces Expansion of Disease State Cells for Bioresearch
HemaCare Corporation (OTCBB: HEMA), a leading provider of human blood and immune cells for bioresearch announced today that it has expanded its portfolio of disease state materials in response to increased demand from therapeutic and diagnostic developers. Recent additions to the portfolio...
Source: Business Wire
Date: July, 17 2017 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1613.0513.0013.0513.001,465
2018-08-1512.7512.5013.2512.5013,650
2018-08-1412.6012.7516.0012.6035,341
2018-08-1313.1713.0013.1712.506,745
2018-08-1013.0013.2013.2013.003,207

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-156,27317,45035.9484Short
2018-08-1421,31035,34160.2982Short
2018-08-134,1186,74561.0526Short
2018-08-106823,20721.2660Cover
2018-08-0928,00436,83876.0193Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HEMA.


About HemaCare Corp. (OTC: HEMA)

Logo for HemaCare Corp. (OTC: HEMA)

HemaCare Corporation is a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy. Our expertise has evolved through years in the business of blood collection, processing and storage. In addition we have established a robust donor recruitment and management system which supports an extensive registry of well characterized repeat donors. HemaCare s controlled procedures ensure a readily available inventory of high quality, consistent and selectable primary human cells and biological products for advanced biomedical research. Our customers are engaged in basic research and development of clinical therapies that are designed to manipulate the immune system for treatment and cure of cancer, degenerative diseases and immune and genetic disorders. HemaCare s products and services address several key markets, including immune therapy research, cell manufacturing for clinical therapy, and clinical laboratory instrument development. We specialize in custom cell collections for customers who may require donors with specific attributes phenotypic or disease state, for example , or sub sets of immune cells that can be selected in our laboratory using the latest technology. HemaCare s products and services address all stages of cell therapy development, from basic biological research in academic institutions to pharmaceutical cell development in large drug companies.

 

Contact Information

 

 

Current Management

  • Pete van der Wal / President, CEO
  • Rochelle Martel / Corporate Secretary, CFO
  • Nestor Montano / Corporate Controller
  • Steve B Gerber, MD / Chairman
  • James G. Wolf / Director, Audits, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Gil Avidar /
  • George Scholl / Compensation Committee Member
  • Terry Van Der Tuuk / Audit Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $70,837,830 - 03/09/2018
  • Authorized: 40,000,000 - 12/31/2016
  • Issue and Outstanding: 11,612,759 - 06/30/2017

 


Recent Filings from (OTC: HEMA)

Annual Report - 2017 Audited Financial Statements
Filing Type: Annual Report - 2017 Audited Financial StatementsFiling Source: OTC Markets
Filing Date: March, 08 2018
Semi-Annual Report - HemaCare Corporation June 30, 2017 Financial Statements
Filing Type: Semi-Annual Report - HemaCare Corporation June 30, 2017 Financial StatementsFiling Source: OTC Markets
Filing Date: August, 21 2017
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: June, 28 2017

 

 


Daily Technical Chart for (OTC: HEMA)

Daily Technical Chart for (OTC: HEMA)


Stay tuned for daily updates and more on (OTC: HEMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HEMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HEMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of HEMA and does not buy, sell, or trade any shares of HEMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/